A successful IDD program at Aurigene involves the participation of different domains like Medicinal Chemistry, Biochemistry, Cell & Molecular Biology, CADD, Analytical Chemistry, DMPK, Pharmacology, Safety and Toxicology, Scale-up & Process Development, Intellectual Property Management and Project Management. Amalgamation of 600+ highly skilled scientists in discovery team and state-of-the-art infrastructure at our Hyderabad and Bangalore sites, has resulted in successful delivery of many IND candidates. Our service is not limited to pharma and biotech companies, but also extend to animal health and crop science sectors.
We are flexible in our approach and offer a variety of business models including FTE & FFS mode of collaboration. In addition to the end-to-end IDD programs, we also offer a variety of “combination” packages to choose from, where our collaborators could select based on their unique requirements. Aurigene provides conducive environment for scientific innovation, which has resulted in several IND filings and a plethora of peer reviewed literature published in journals of international repute. We also bring with us a track record of solving complex challenges, using newer chemical modalities like peptides, PROTACs, lipids and Oligonucleotides.
18 years’ experience in drug discovery
Various customer models
65+ Integrated Drug Discovery projects delivered
Speed: Our average candidate nomination time is 24-28 months
Capabilities to apply multiple modalities
Seamless integration into development stages
Integrated project management
JUNE 28, 2022
An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...Read More
Genomics plays a vital role in identifying which gene is associated with a specific disease. A gene called CNOT1 is for example known for it's effect on brain development and for impairing memory and learning. Despite the great promise genomics provides in understanding the disease, genes are not the best drug targets....Read More
Backed by our strong chemistry, we enable “Finger-print” protein structure and functional characterization for proteins from naked proteins to hyperglycosylated or derivatized proteins. ...Read More
Background: Develop oral liquid dosage form of an IND candidate (small molecule) suitable for chronic toxicology studies in rats. Must meet required systemic exposure and shall be dose proportional. Developed vehicle or used excipients shall be safe for chronic preclinical toxicology studies. Challenges: Low oral bioavailability Practically insoluble in bio relev...Read More
A conceptually new three-component reaction was developed to construct a six-membered fused N-heterocyclic ring affording (pyrazolo)pyrimidines/pyridines as potential inhibitors of PDE4. The reaction is catalyzed by triflic acid in acetic acid in the presence of aerial oxygen. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis . It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization . IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.